PAION Pharma nimmt BYFAVO® (Remimazolam) zum 1. September 2026 aus dem deutschen Markt zurück. Im Rahmen der Erstattungsbetragsverhandlungen mit dem GKV-Spitzenverband
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information